MeSH tree: D02.257
Neuromuscular training reduces the onset of chemotherapy-induced peripheral neuropathy (CIPN), according to a study published online July 1 in JAMA Internal Medicine.
Jul 22, 2024
0
26
Colorectal cancer is the second leading cause of cancer deaths worldwide and the third most diagnosed cancer, affecting over a million people annually. The problem worsens if the tumor is metastatic, meaning it moves from ...
Jul 15, 2024
0
39
Cancer treatments often cause nerve damage that can lead to long-lasting symptoms. Medication has proven ineffective in these cases. A sports scientist at the University of Basel, together with an interdisciplinary team from ...
Jul 1, 2024
0
61
The National Comprehensive Cancer Network (NCCN)—a nonprofit alliance of leading cancer centers—is publishing new results for its latest survey on cancer drug shortages in the United States. This follows data published one ...
Jun 26, 2024
0
21
Inflammatory bowel disease (IBD) is a common chronic gastrointestinal disorder and current treatment strategies can cause adverse effects. Thus, there is a need to identify alternative compounds to treat IBD. Similarly, the ...
Apr 30, 2024
0
36
In many cancers, such as ovarian cancer, each round of chemotherapy kills the majority of cancer cells, while a small population of them survives through treatment. These cells are typically more resistant for the next cycle ...
Feb 12, 2024
0
61
The current standard of care for treating patients with stage 3 colon cancer is to use adjuvant therapy with FOLFOX, a combination of the drugs fluorouracil, leucovorin, and oxaliplatin. Although effective, the use of oxaliplatin ...
Feb 6, 2024
0
44
Tisch Cancer Institute researchers have discovered that a certain type of chemotherapy improves the immune system's ability to fight off bladder cancer, particularly when combined with immunotherapy.
Jan 26, 2024
0
58
Immunotherapy in combination with chemotherapy has become an important therapeutic treatment option in some patients with metastatic breast cancer. Which patients will benefit the most, however, remains unclear; current biomarkers ...
Dec 14, 2023
0
46
For patients with EGFR-mutated advanced non-small cell lung cancer (NSCLC), osimertinib with chemotherapy leads to significantly longer progression-free survival (PFS) compared with osimertinib alone, according to a study ...
Nov 16, 2023
0
45
